Standard BioTools, Inc. (LAB) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$0.63

From 52W high−63.33%

Volume1.02M

Market cap$243.19M

P/E (TTM)—

P/S (TTM)2.9x

Div yield—

Key dataNov 4, 2026

Open

$0.63

From 52W high

−63.33%

Volume

1.02M

Market cap

$243.19M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

2.3x

P/E (TTM)

—

RSI (14)

38.2

MomentumView details →

1D Return

+0.85%

YTD Return

−52.39%

SummaryUpdated Sep 1, 2026

Standard BioTools Inc. (NASDAQ:LAB) is a life sciences tools company that was founded in 1999 as Fluidigm Corporation and rebranded to its current name in April 2022. The company designs, manufactures, and markets specialized scientific instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. Standard BioTools underwent a significant transformation in January 2024 when it merged with SomaLogic, a proteomics company, creating a diversified platform focused on multi-omics research tools. The company is headquartered in South San Francisco, California, and serves academic research institutions, pharmaceutical companies, biotechnology firms, and clinical laboratories globally.

Ask drillr about Standard BioTools, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

2.3x

EV/Sales

−2.3x

P/S (TTM)

2.9x

P/B (TTM)

0.4x

ProfitabilityView details →

Gross Margin

50.82%

Net Margin

−46.44%

EBITDA Margin

−96.86%

ROE (TTM)

−7.06%

ROA (TTM)

−6.17%

Asset Turnover

0.13x

GrowthView details →

Revenue YoY

−22.01%

EPS YoY

+67.73%

FCF YoY

+33.29%

Revenue CAGR 3Y

−4.49%

EPS CAGR 3Y

+61.54%

EBITDA YoY

+12.05%

MomentumView details →

1D Return

+0.85%

YTD Return

−52.39%

1Y Return

−46.54%

RSI (14)

38.2

vs 50D SMA

−10.06%

vs 200D SMA

−32.39%

Capital & dividendView details →

Debt/Equity

0.05x

Current Ratio

9.75x

Quick Ratio

9.40x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.03

EPS Surprise

250.00%

Beats (12Q)

6/12

Next Q EPS Est

−$0.02

Avg Surprise (4Q)

25.25%

Rev Surprise

3.11%

Financials snapshotView financials →

Revenue (TTM)

84.43M

Net Income (TTM)

−39.21M

Op. CF (TTM)

−64.27M

Next earningsMar 3, 2027 →

Latest newsMore news →

ARCHIMED Life Science Tools & Services completed its acquisition of STANDARD BIOTOOLS INC.' microfluidics business, which will operate as Biomark Scientific.2d ago

Standard BioTools Inc. entered into a definitive agreement to sell its Microfluidics business to healthcare-focused investment firm ARCHIMED.30d ago

Similar companies

TriSalus Life Sciences, Inc.TLSI Profound Medical Corp.PROF Austar Lifesciences Limited06118.HK Anika Therapeutics, Inc.ANIK Broncus Holding Corporation02216.HK RxSight, Inc.RXST Find similar companies →

Latest newsMore news →

ARCHIMED Life Science Tools & Services completed its acquisition of STANDARD BIOTOOLS INC.' microfluidics business, which will operate as Biomark Scientific.2d ago Standard BioTools Inc. entered into a definitive agreement to sell its Microfluidics business to healthcare-focused investment firm ARCHIMED.30d ago Standard BioTools entered into a new purchase agreement with Element Biosystems, a subsidiary of GMT Venture, to sell its mass cytometry business after deeming GMT Venture's unsolicited acquisition proposal superior.35d ago